Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection

Overview

Journal Antiviral Res

Publisher Elsevier

Date 2020 May 4

PMID 32360182

Citations 266

Authors

Emily Mantlo

Natalya Bukreyeva

Junki Maruyama

Slobodan Paessler

Cheng Huang

Affiliations

Soon will be listed here.

Abstract

There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.

Citing Articles

Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseases.

Yalcin Mutlu M, Kleyer A, Kroenke G, Fagni F, Temiz S, Meder C BMJ Open. 2025; 15(1):e088486.

PMID: 39773803 PMC: 11749532. DOI: 10.1136/bmjopen-2024-088486.

Protective effect of interferon type I on barrier function of human airway epithelium during rhinovirus infections in vitro.

Boland H, Endres A, Kinscherf R, Schubert R, Wilhelm B, Schwarzbach H Sci Rep. 2024; 14(1):30510.

PMID: 39681656 PMC: 11649702. DOI: 10.1038/s41598-024-82516-2.

A pH-triggered self-releasing humic acid hydrogel loaded with porcine interferon α/γ achieves anti-pseudorabies virus effects by oral administration.

Sun M, Shi Y, Lei B, Zhang W, Feng J, Ge S Vet Res. 2024; 55(1):153.

PMID: 39568063 PMC: 11580204. DOI: 10.1186/s13567-024-01411-w.

Vaccination and Therapeutics.

Abdella W, Selim A, Diab S, Qobeia E, Elgazzar A Adv Exp Med Biol. 2024; 1457:165-184.

PMID: 39283426 DOI: 10.1007/978-3-031-61939-7_9.

Interferon-stimulated genes and their antiviral activity against SARS-CoV-2.

Ortega-Prieto A, Jimenez-Guardeno J mBio. 2024; 15(9):e0210024.

PMID: 39171921 PMC: 11389394. DOI: 10.1128/mbio.02100-24.

References

Siu K, Kok K, Ng M, Poon V, Yuen K, Zheng B . Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J Biol Chem. 2009; 284(24):16202-16209. PMC: 2713514. DOI: 10.1074/jbc.M109.008227. View

Chan J, Kok K, Zhu Z, Chu H, To K, Yuan S . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1):221-236. PMC: 7067204. DOI: 10.1080/22221751.2020.1719902. View

Pestka S, Krause C, Walter M . Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004; 202:8-32. DOI: 10.1111/j.0105-2896.2004.00204.x. View

Narayanan K, Huang C, Lokugamage K, Kamitani W, Ikegami T, Tseng C . Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008; 82(9):4471-9. PMC: 2293030. DOI: 10.1128/JVI.02472-07. View

Kamitani W, Huang C, Narayanan K, Lokugamage K, Makino S . A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat Struct Mol Biol. 2009; 16(11):1134-40. PMC: 2784181. DOI: 10.1038/nsmb.1680. View

Moriguchi H, Sato C . Treatment of SARS with human interferons. Lancet. 2003; 362(9390):1159. PMC: 7134868. DOI: 10.1016/S0140-6736(03)14484-4. View

Kamitani W, Narayanan K, Huang C, Lokugamage K, Ikegami T, Ito N . Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc Natl Acad Sci U S A. 2006; 103(34):12885-90. PMC: 1568942. DOI: 10.1073/pnas.0603144103. View

Narayanan K, Huang C, Makino S . SARS coronavirus accessory proteins. Virus Res. 2007; 133(1):113-21. PMC: 2720074. DOI: 10.1016/j.virusres.2007.10.009. View

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

10.

Honda K, Takaoka A, Taniguchi T . Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006; 25(3):349-60. DOI: 10.1016/j.immuni.2006.08.009. View

11.

Kash J, Muhlberger E, Carter V, Grosch M, Perwitasari O, Proll S . Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol. 2006; 80(6):3009-20. PMC: 1395418. DOI: 10.1128/JVI.80.6.3009-3020.2006. View

12.

Huang C, Lokugamage K, Rozovics J, Narayanan K, Semler B, Makino S . SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog. 2011; 7(12):e1002433. PMC: 3234236. DOI: 10.1371/journal.ppat.1002433. View

13.

Frieman M, Ratia K, Johnston R, Mesecar A, Baric R . Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol. 2009; 83(13):6689-705. PMC: 2698564. DOI: 10.1128/JVI.02220-08. View

14.

Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H . Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003; 361(9374):2045-6. PMC: 7112442. DOI: 10.1016/s0140-6736(03)13615-x. View

15.

Desmyter J, Melnick J, Rawls W . Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol. 1968; 2(10):955-61. PMC: 375423. DOI: 10.1128/JVI.2.10.955-961.1968. View

16.

Sun L, Xing Y, Chen X, Zheng Y, Yang Y, Nichols D . Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One. 2012; 7(2):e30802. PMC: 3270028. DOI: 10.1371/journal.pone.0030802. View

17.

Schoggins J, Rice C . Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2012; 1(6):519-25. PMC: 3274382. DOI: 10.1016/j.coviro.2011.10.008. View

18.

Schoggins J, Wilson S, Panis M, Murphy M, Jones C, Bieniasz P . A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. PMC: 3409588. DOI: 10.1038/nature09907. View

19.

Devaraj S, Wang N, Chen Z, Chen Z, Tseng M, Barretto N . Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem. 2007; 282(44):32208-21. PMC: 2756044. DOI: 10.1074/jbc.M704870200. View

20.

Strayer D, Dickey R, Carter W . Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans. Infect Disord Drug Targets. 2014; 14(1):37-43. DOI: 10.2174/1871526514666140713152858. View